Get startedLog in
    Picture of Hyloris Pharmaceuticals SA logo

    HYL — Hyloris Pharmaceuticals SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapNeutral
    All News

    Brief: Pleco Therapeutics Receives FDA Orphan Drug Designation

    Picture of Hyloris Pharmaceuticals SA logoHyloris Pharmaceuticals SA
    16/01/2024 17:04
    Jan 16 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * PLECO THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
    * PTX-252 IS A NOVEL MOLECULAR ENTITY DEVELOPED TO INCREASE
SENSITIVITY OF CANCER CELLS TO CHEMOTHERAPY
    * FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO PLECO
THERAPEUTICS
BV'S LEAD COMPOUND, PTX-252 FOR TREATMENT OF ACUTE MYELOID
LEUKAEMIA (AML)

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX7m5d1M
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))

    Recent news on Hyloris Pharmaceuticals SA

    See all news